The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Ashtead Rises After Strong First Quarter

Tue, 11th Sep 2018 10:41

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Ashtead Group, up 2.5%. The equipment rentals firm said it will increase and extend its current share buyback programme following profit growth in the first quarter of current financial year. Ashtead said revenue in the three months to the end of July rose 22% to GBP1.05 billion from GBP880.1 million reported a year earlier, pushing pretax profit up 23% to GBP274.4 million from GBP228.9 million. Ashtead said the results were driven by strong organic growth, supplemented by bolt-on acquisitions, most notably the purchase of bulldozers retailer CRS in August last year. During the quarter, the company said it bought back 4.1 million shares, totalling GBP94 million. To date, Ashtead has spent GBP300 million under the share buyback programme announced in December last year. The company said it intends to increase and extend its buyback plans, increasing the spend to GBP125 million per quarter and resulting in a total outlay of GBP675 million in financial 2019. The company also revealed plans for a new share buyback programme in financial 2020, with an anticipated spend of at least GBP500 million.----------FTSE 100 - LOSERS----------BHP Billiton, down 1.5%. The Anglo-Australian miner was cut to Hold from Buy by Deutsche Bank. ----------FTSE 250 - WINNERS----------JD Wetherspoon, up 2.2%. Berenberg raised the pub chain to Buy from Hold.----------Hilton Food Group, up 2.1%. The food packaging company said it is confident in the company's future growth after posting an increase in profit and revenue for the first half of the year. For the 28 weeks to July 15, the firm posted 14% rise in pretax profit to GBP21.0 million from GBP18.4 million a year ago. This was as revenue jumped by 25% to GBP863.6 million from GBP690.7 million. Earnings before interest, taxes, depreciation and amortisation increased to GBP35.5 million from GBP29.6 million in the comparative year ago period, "broadly" reflecting the new Seachill, business which was acquired in November 2017 and has "delivered on expectations", Hilton Food said. The company upped its interim dividend by 12% to 5.6 pence from 5.0p a year prior.----------Sanne Group, up 2.0%. The fund administrator said its profit for the first half of 2018 came in lower year-on-year due to the integration expenses associated with IFS Group. Sanne said pretax profit declined 13% to GBP10.9 million in the six months to June 30 compared to GBP12.5 million reported for the same period a year ago, despite revenue jumping by 17% to GBP65.9 million from GBP56.3 million. However, the company said it saw a good organic growth across all of its divisions, supported by acquisition of alternative investment fund LIS in February, which contributed for five months of the period. Sanne said this acquisition provided a number of good cross-selling opportunities and exposure to a new range of institutional real estate fund managers. As a result, revenue in the Europe, the Middle East & Africa Alternatives division rose by 41% to GBP32.7 million from GBP23.1 million.----------FTSE 250 - LOSERS----------Cairn Energy, down 5.0%. The oil and gas explorer said it swung to a loss in the first half of its financial year on the back of constrained production and downtime and fair value losses. For the six months to June 30, the company posted a pretax loss of USD602.9 million, compared to a USD77.7 million profit in the half-year period last year. This was due to the company swinging to a USD319.4 million loss on the fair value of its financial assets compared to a USD200.5 million profit the year prior. The swing to a loss on financial assets was mainly caused by Cairn's 3% stake in Vedanta Ltd. Cairn recognized a USD230.8 million loss on the holding, after it was sold on the demand of the Indian tax authority and USD231 million in proceeds from the sale seized. Cairn said it remains confident of its legal position in the tax dispute.----------Elementis, down 3.9% at 243.00 pence. The speciality chemicals company said it will now pay USD553 million to acquire Dutch industrial talc mineral additive firm Mondo Minerals Holding instead of USD600 million agreed previously. The company, which was forced to reconsider the Mondo deal due to shareholder concerns, will pay USD500 million in cash to Advent Mondo (Luxembourg) to buy Mondo plus USD53.0 million in earn-out payments upon subject to the achievement of certain performance targets by Mondo. It intends to fund the deal via a USD230 million rights issue of shares and by utilising a new USD775.0 million term and revolving credit facility. The right issue will be on the basis of 1 new ordinary share at 152.0 pence per share for every 4 existing shares, and Elementis will offer up to 116.0 million new shares.----------OTHER MAIN MARKET AND AIM - WINNERS----------Produce Investments, up 32% at 187.20p. The fresh potato and daffodil producer said it reached an agreement with Promethean Investments for acquisition of the company by a Promethean vehicle April 1983 Bidco. The offer of 193 pence per share in cash values Produce as a whole at GBP53.0 million. The 193p offer is a 35% premium on the company's closing price of 143p on Monday. The Promethean offer includes a partial share and loan note alternative under which Produce shareholders will be able to elect to receive 98.43p in cash and one unit. Each unit comprises one April 1983 share and one April loan note. Produce's board said it "considers the terms of the offer to be fair and reasonable". ----------IXICO, up 24%. The brain medicine developer said it inked a new contract worth GBP9.1 million with an unnamed "top-10 global pharmaceutical company". The contract which lasts over a four-year term is for the provision of IXICO's technology-enabled imaging services in support of a study of Huntington's disease, a genetic neurodegenerative disorder affecting movement, cognition and behaviour. As part of the study, IXICO will optimise, standardise and collect magnetic resonance imaging data from specialist imaging centres. Afterwards, the company's "data science expertise and artificial intelligence software algorithms will be applied to provide insights into brain cellular microstructure and neuronal connectivity to support the evaluation of drug safety and efficacy", IXICO explained.----------OTHER MAIN MARKET AND AIM - LOSERS----------Haydale Graphene, down 14%. The graphene materials firm said it is holding talks with the Amiblu Technology research team to discuss "the next steps" after a disappointing trial to develop a new pipeline product. The results of a trial in March for Amiblu Technology, formerly Flowtite Technology, "did not show the improvements Haydale had hoped for", the company explained. Amiblu Technology is the glass fibre reinforced plastic pipe technology and research and development centre of the Saudi Arabian Amiantit Co with which Haydale partnered to develop glass fibre reinforced plastic products in May 2016.----------
More News
17 Jan 2017 08:47

Giulio Cerroni appointed CEO of IXICO

(ShareCast News) - Brain health company IXICO announced on Tuesday that Giulio Cerroni will be appointed to the board as chief executive officer, with effect from 6 February. The AIM-traded firm said Derek Hill, the co-founder and current CEO, will remain on the board and continue to serve as an exe

Read more
16 Nov 2016 10:01

Ixico joins European syndicate to collect data on Alzheimer's

(ShareCast News) - Brain health company Ixico is to receive €100,000 to provide digital technologies for collection and analysis of data , which further expands its work on wearable bio-sensors as part of a pan-European partnership. The AIM-listed company is to participate in a new collaborative EU

Read more
21 Oct 2016 10:15

Ixico's income falls slightly but has a number of contracts in the pipeline

(ShareCast News) - AIM-listed Ixico's income for the year fell, but the brain health company has a number of contracts with pharmaceuticals in the pipeline and a "strong" balance sheet. In trading update for the year ended 30 September, the company reported revenues of £3.1m and other income of £700

Read more
20 Oct 2016 11:01

Ixico pens deal to help develop a therapy for Parkinson's like diesease

(ShareCast News) - Shares in AIM-listed Ixico rose above 22% on Thursday, as the brain health company announced it had signed a $1.2m contract with a global pharmaceutical for imaging clinical trial services for a Parkinson's-like neurodegenerative disease. The project is for a second phase clinical

Read more
10 Oct 2016 12:26

Ixico to receive €1m from EU Alzheimer's project

(ShareCast News) - AIM-listed pharmaceutical Ixico is to receive €1m as a partner in an EU public-private consortium, which has the potential for long-term revenue through the development of diagnostic and disease management technologies for Alzheimer's. Ixico is to work on the Amyloid Imaging to Pr

Read more
2 Jun 2016 16:27

IXICO study joins Dementias Platform

(ShareCast News) - Brain health company IXICO announced on Thursday that its Cygnus study has joined the high-profile Dementias Platform UK (DPUK). The AIM-traded firm described Cygnus as a real-world digital data collection study from people with cognitive impairment and dementia. It said the four

Read more
18 Jan 2016 13:51

Ixico wins four new contracts worth over £3m

(ShareCast News) - Brain health company Ixico was recently awarded four new contracts with "leading" pharmaceutical groups and a specialist biotechnology firm totalling over £3m in value. The contracts involve global clinical trials of novel drugs for Alzheimer's disease spanning three major phases

Read more
19 Oct 2015 12:33

Ixico full-year income in line with expectations

(ShareCast News) - Brain health company Ixico reported revenues for the year of £3.1m and other income at £1m, in line with market expectations and giving a total combined income of £4.1m. This was down from £4.3m for the 16-month period to 30 September 2014. In a pre-close trading update ahead of

Read more
29 Jun 2015 11:11

Ixico secures two clinical trial contracts alongside partner VirtualScopics

Ixico has won two contracts to deploy its products in unnamed pharmaceutical companies' clinical trials, alongside its partner VirtualScopics. Both studies will employ Ixico's TrialTracker digital platform to collect and image data, one pertaining to metastatic solid tumours and the other to rare ne

Read more
17 Sep 2014 08:48

IXICO Appoints CFO For October 1 Start

Read more
21 Jul 2014 15:45

DIRECTOR DEALINGS: IXICO Divisional Vice-President Buys Shares

Read more
18 Jul 2014 07:25

UK MORNING BRIEFING: Shares Lower On Ukraine Crash, Gaza Offensive

Read more
19 Jun 2014 10:40

IXICO Joins Medical Research Council Collaboration For Dementia Drive

LONDON (Alliance News) - IXICO PLC said Thursday it will take part in a GBP16 million collaboration launched by publicly funded government agency the Medical Research Council to speed up research into dementia. The MRC has launched the UK Dementias Research Platform with the aim of seeking

Read more
19 Jun 2014 08:30

Ixico partners with the Medical Research Council to launch UK Dementias Research Platform

Biotechnology group Ixico has partnered with the Medical Research Council (MRC) to launch the UK Dementias Research Platform (UKDP), a £16m public-private partnership. The group, which set up the partnership to speed up research into dementias, will act as the MRC's imaging partner on the project a

Read more
6 Jun 2014 09:20

IXICO To Meet Full-Year Expectations As Interim Hit By Listing Costs

LONDON (Alliance News) - IXICO PLC expressed confidence Friday in meeting market expectations for the full year, as it swung into a loss in the half year to end-March, hit by costs relating to its AIM listing and a decline in revenues. The company was formed via the reverse takeover of Phyt

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.